Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy.

Silva M, Ferreira PE, Otienoburu SD, Calçada C, Ngasala B, Björkman A, Mårtensson A, Gil JP, Veiga MI.

J Antimicrob Chemother. 2019 Jul 1;74(7):1890-1893. doi: 10.1093/jac/dkz098.

PMID:
30869127
2.

Prevalence of and Risk Factors Associated with Polymerase Chain Reaction-Determined Plasmodium falciparum Positivity on Day 3 after Initiation of Artemether-Lumefantrine Treatment for Uncomplicated Malaria in Bagamoyo District, Tanzania.

Mwaiswelo R, Ngasala B, Jovel I, Xu W, Larsson E, Malmberg M, Gil JP, Premji Z, Mmbando BP, Mårtensson A.

Am J Trop Med Hyg. 2019 May;100(5):1179-1186. doi: 10.4269/ajtmh.18-0729.

3.

Plasmodium falciparum Plasmepsin 2 Duplications, West Africa.

Inoue J, Silva M, Fofana B, Sanogo K, Mårtensson A, Sagara I, Björkman A, Veiga MI, Ferreira PE, Djimde A, Gil JP.

Emerg Infect Dis. 2018 Aug;24(8). doi: 10.3201/eid2408.180370. Epub 2018 Aug 17.

4.

The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome.

Kiaco K, Rodrigues AS, do Rosário V, Gil JP, Lopes D.

Malar J. 2017 Sep 21;16(1):383. doi: 10.1186/s12936-017-2006-6.

5.

Sustained High Cure Rate of Artemether-Lumefantrine against Uncomplicated Plasmodium falciparum Malaria after 8 Years of Its Wide-Scale Use in Bagamoyo District, Tanzania.

Mwaiswelo R, Ngasala B, Gil JP, Malmberg M, Jovel I, Xu W, Premji Z, Mmbando BP, Björkman A, Mårtensson A.

Am J Trop Med Hyg. 2017 Aug;97(2):526-532. doi: 10.4269/ajtmh.16-0780.

6.

MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.

Vos K, Sciuto CL, Piedade R, Ashton M, Björkman A, Ngasala B, Mårtensson A, Gil JP.

Pharmacogenomics. 2017 Jul;18(10):981-985. doi: 10.2217/pgs-2017-0032. Epub 2017 Jun 22.

PMID:
28639487
7.

pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.

Gil JP, Krishna S.

Expert Rev Anti Infect Ther. 2017 Jun;15(6):527-543. doi: 10.1080/14787210.2017.1313703. Epub 2017 Apr 10. Review.

PMID:
28355493
8.

Plasmodium falciparum drug resistance in Angola.

Fançony C, Brito M, Gil JP.

Malar J. 2016 Feb 9;15:74. doi: 10.1186/s12936-016-1122-z. Review.

9.

Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.

Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé AF, Coulibaly AS, Traore OB, Dara N, Kabore MJ, Thera I, Compaore YD, Sylla MM, Nikiema F, Diallo MS, Dicko A, Gil JP, Borrmann S, Duparc S, Miller RM, Doumbo OK, Shin J, Bjorkman A, Ouedraogo JB, Sirima SB, Djimdé AA.

Lancet Infect Dis. 2016 Feb;16(2):189-98. doi: 10.1016/S1473-3099(15)00318-7. Epub 2015 Oct 23.

10.

Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali.

Ouattara A, Kone A, Adams M, Fofana B, Maiga AW, Hampton S, Coulibaly D, Thera MA, Diallo N, Dara A, Sagara I, Gil JP, Bjorkman A, Takala-Harrison S, Doumbo OK, Plowe CV, Djimde AA.

Am J Trop Med Hyg. 2015 Jun;92(6):1202-6. doi: 10.4269/ajtmh.14-0605. Epub 2015 Apr 27.

11.

Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.

Piedade R, Traub S, Bitter A, Nüssler AK, Gil JP, Schwab M, Burk O.

Antimicrob Agents Chemother. 2015 Jan;59(1):96-104. doi: 10.1128/AAC.04140-14. Epub 2014 Oct 13.

12.

Complex polymorphisms in the Plasmodium falciparum multidrug resistance protein 2 gene and its contribution to antimalarial response.

Veiga MI, Osório NS, Ferreira PE, Franzén O, Dahlstrom S, Lum JK, Nosten F, Gil JP.

Antimicrob Agents Chemother. 2014 Dec;58(12):7390-7. doi: 10.1128/AAC.03337-14. Epub 2014 Sep 29.

13.

Alternatively spliced transcripts and novel pseudogenes of the Plasmodium falciparum resistance-associated locus pfcrt detected in East African malaria patients.

Gadalla NB, Malmberg M, Adam I, Oguike MC, Beshir K, Elzaki SE, Mukhtar I, Gadalla AA, Warhurst DC, Ngasala B, Mårtensson A, El-Sayed BB, Gil JP, Sutherland CJ.

J Antimicrob Chemother. 2015 Jan;70(1):116-23. doi: 10.1093/jac/dku358. Epub 2014 Sep 24.

14.

Artemisinin resistance in Plasmodium falciparum: what is it really?

Ferreira PE, Culleton R, Gil JP, Meshnick SR.

Trends Parasitol. 2013 Jul;29(7):318-20. doi: 10.1016/j.pt.2013.05.002. Epub 2013 Jun 11.

PMID:
23768531
15.

Malaria pharmacogenomics: return to the future.

Gil JP.

Pharmacogenomics. 2013 May;14(7):707-10. doi: 10.2217/pgs.13.41. No abstract available.

PMID:
23651016
16.

Frequency of the functionally relevant aryl hydrocarbon receptor repressor (AhRR) Pro185Ala SNP in Papua New Guinea.

Cavaco I, Hombhanje FW, Gil JP, Kaneko A.

Drug Metab Pharmacokinet. 2013;28(6):519-21. Epub 2013 May 7.

17.

Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -assessment of DNA extraction methods and field applicability.

Morris U, Aydin-Schmidt B, Shakely D, Mårtensson A, Jörnhagen L, Ali AS, Msellem MI, Petzold M, Gil JP, Ferreira PE, Björkman A.

Malar J. 2013 Mar 19;12:106. doi: 10.1186/1475-2875-12-106.

18.

Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania.

Malmberg M, Ngasala B, Ferreira PE, Larsson E, Jovel I, Hjalmarsson A, Petzold M, Premji Z, Gil JP, Björkman A, Mårtensson A.

Malar J. 2013 Mar 18;12:103. doi: 10.1186/1475-2875-12-103.

19.

Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms.

Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, Mårtensson A, Gil JP.

J Infect Dis. 2013 Mar 1;207(5):842-7. doi: 10.1093/infdis/jis747. Epub 2012 Dec 5.

20.

Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.

Fröberg G, Ferreira PE, Mårtensson A, Ali A, Björkman A, Gil JP.

Antimicrob Agents Chemother. 2013 Feb;57(2):887-92. doi: 10.1128/AAC.00950-12. Epub 2012 Dec 3.

21.

CYP2C8 status of patients with malaria influences selection of Plasmodium falciparum pfmdr1 alleles after amodiaquine-artesunate treatment.

Cavaco I, Mårtensson A, Fröberg G, Msellem M, Björkman A, Gil JP.

J Infect Dis. 2013 Feb 15;207(4):687-8. doi: 10.1093/infdis/jis736. Epub 2012 Nov 30. No abstract available.

PMID:
23204183
22.

Quinine treatment selects the pfnhe-1 ms4760-1 polymorphism in Malian patients with Falciparum malaria.

Kone A, Mu J, Maiga H, Beavogui AH, Yattara O, Sagara I, Tekete MM, Traore OB, Dara A, Dama S, Diallo N, Kodio A, Traoré A, Björkman A, Gil JP, Doumbo OK, Wellems TE, Djimde AA.

J Infect Dis. 2013 Feb 1;207(3):520-7. doi: 10.1093/infdis/jis691. Epub 2012 Nov 16.

23.

Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar.

Fröberg G, Jörnhagen L, Morris U, Shakely D, Msellem MI, Gil JP, Björkman A, Mårtensson A.

Malar J. 2012 Sep 11;11:321. doi: 10.1186/1475-2875-11-321.

24.

Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands.

Cavaco I, Piedade R, Msellem MI, Bjorkman A, Gil JP.

Trop Med Int Health. 2012 Jul;17(7):854-7. doi: 10.1111/j.1365-3156.2012.03011.x. Epub 2012 May 18.

25.

Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms.

Burk O, Piedade R, Ghebreghiorghis L, Fait JT, Nussler AK, Gil JP, Windshügel B, Schwab M.

Br J Pharmacol. 2012 Oct;167(3):666-81. doi: 10.1111/j.1476-5381.2012.02033.x.

26.

pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine.

Veiga MI, Ferreira PE, Malmberg M, Jörnhagen L, Björkman A, Nosten F, Gil JP.

Antimicrob Agents Chemother. 2012 Jul;56(7):3615-9. doi: 10.1128/AAC.06350-11. Epub 2012 Apr 16.

27.

PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin.

Piedade R, Schaeffeler E, Winter S, Asimus S, Schwab M, Ashton M, Burk O, Gil JP.

Antimicrob Agents Chemother. 2012 Apr;56(4):2153-7. doi: 10.1128/AAC.06009-11. Epub 2012 Jan 17.

28.

Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria.

Carlsson AM, Ngasala BE, Dahlström S, Membi C, Veiga IM, Rombo L, Abdulla S, Premji Z, Gil JP, Björkman A, Mårtensson A.

Malar J. 2011 Dec 20;10:380. doi: 10.1186/1475-2875-10-380.

29.

PfMDR1: mechanisms of transport modulation by functional polymorphisms.

Ferreira PE, Holmgren G, Veiga MI, Uhlén P, Kaneko A, Gil JP.

PLoS One. 2011;6(9):e23875. doi: 10.1371/journal.pone.0023875. Epub 2011 Sep 1.

30.

The pharmacogenetics of antimalaria artemisinin combination therapy.

Piedade R, Gil JP.

Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1185-200. doi: 10.1517/17425255.2011.608660. Epub 2011 Sep 8. Review.

PMID:
21899476
31.

Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance.

Veiga MI, Ferreira PE, Jörnhagen L, Malmberg M, Kone A, Schmidt BA, Petzold M, Björkman A, Nosten F, Gil JP.

PLoS One. 2011;6(5):e20212. doi: 10.1371/journal.pone.0020212. Epub 2011 May 25.

32.

Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial.

Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Björkman A, Mårtensson A.

Clin Infect Dis. 2011 Apr 1;52(7):873-82. doi: 10.1093/cid/cir066.

PMID:
21427394
33.

Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study.

Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, Bergqvist Y, Gil JP, Premji Z, Mårtensson A.

Malar J. 2011 Mar 16;10:64. doi: 10.1186/1475-2875-10-64.

34.

Antimalarial exposure delays Plasmodium falciparum intra-erythrocytic cycle and drives drug transporter genes expression.

Veiga MI, Ferreira PE, Schmidt BA, Ribacke U, Björkman A, Tichopad A, Gil JP.

PLoS One. 2010 Aug 25;5(8):e12408. doi: 10.1371/journal.pone.0012408.

35.

Pharmacogenetics of antimalarial drugs: effect on metabolism and transport.

Kerb R, Fux R, Mörike K, Kremsner PG, Gil JP, Gleiter CH, Schwab M.

Lancet Infect Dis. 2009 Dec;9(12):760-74. doi: 10.1016/S1473-3099(09)70320-2. Review.

PMID:
19926036
36.

Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa.

Dahlström S, Ferreira PE, Veiga MI, Sedighi N, Wiklund L, Mårtensson A, Färnert A, Sisowath C, Osório L, Darban H, Andersson B, Kaneko A, Conseil G, Björkman A, Gil JP.

J Infect Dis. 2009 Nov 1;200(9):1456-64. doi: 10.1086/606009.

PMID:
19807279
37.

Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment.

Dahlström S, Veiga MI, Mårtensson A, Björkman A, Gil JP.

Antimicrob Agents Chemother. 2009 Jun;53(6):2553-6. doi: 10.1128/AAC.00091-09. Epub 2009 Apr 13.

38.

In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa.

Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, Fidock DA, Gil JP.

J Infect Dis. 2009 Mar 1;199(5):750-7. doi: 10.1086/596738.

39.

Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Veiga MI, Asimus S, Ferreira PE, Martins JP, Cavaco I, Ribeiro V, Hai TN, Petzold MG, Björkman A, Ashton M, Gil JP.

Eur J Clin Pharmacol. 2009 Apr;65(4):355-63. doi: 10.1007/s00228-008-0573-8. Epub 2008 Nov 1.

PMID:
18979093
40.

Pharmacogenetic tools for malaria and TB in the Developing World.

Ferreira PE, Cavaco I, Gil JP.

Per Med. 2008 Nov;5(6):627-639. doi: 10.2217/17410541.5.6.627.

PMID:
29788622
41.

Amodiaquine pharmacogenetics.

Gil JP.

Pharmacogenomics. 2008 Oct;9(10):1385-90. doi: 10.2217/14622416.9.10.1385. Review.

PMID:
18855526
42.

Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6).

Dahlström S, Veiga MI, Ferreira P, Mårtensson A, Kaneko A, Andersson B, Björkman A, Gil JP.

Infect Genet Evol. 2008 May;8(3):340-5. doi: 10.1016/j.meegid.2008.02.002. Epub 2008 Feb 15.

PMID:
18359278
43.

Polymorphism of antimalaria drug metabolizing, nuclear receptor, and drug transport genes among malaria patients in Zanzibar, East Africa.

Ferreira PE, Veiga MI, Cavaco I, Martins JP, Andersson B, Mushin S, Ali AS, Bhattarai A, Ribeiro V, Björkman A, Gil JP.

Ther Drug Monit. 2008 Feb;30(1):10-5. doi: 10.1097/FTD.0b013e31815e93c6.

PMID:
18223457
44.

Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine.

Echeverry DF, Holmgren G, Murillo C, Higuita JC, Björkman A, Gil JP, Osorio L.

Am J Trop Med Hyg. 2007 Dec;77(6):1034-8.

PMID:
18165517
45.

Carriers, channels and chloroquine efficacy in Guinea-Bissau.

Ursing J, Rombo L, Kofoed PE, Gil JP.

Trends Parasitol. 2008 Feb;24(2):49-51. doi: 10.1016/j.pt.2007.11.002. Epub 2007 Dec 31.

PMID:
18165155
46.

The Vietnamese Khin population harbors particular N-acetyltransferase 2 allele frequencies.

Cavaco I, Asimus S, Peyrard-Janvid M, Ferreira PE, Veiga MI, Hai TN, Ribeiro V, Ashton M, Gil JP.

Clin Chem. 2007 Nov;53(11):1977-9. No abstract available.

PMID:
17954500
47.

The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa.

Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, Krishna S, Gil JP.

Trop Med Int Health. 2007 Jun;12(6):736-42.

48.

Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau.

Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP.

Am J Trop Med Hyg. 2007 May;76(5):844-8.

PMID:
17488902
49.

Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa.

Holmgren G, Hamrin J, Svärd J, Mårtensson A, Gil JP, Björkman A.

Infect Genet Evol. 2007 Sep;7(5):562-9. Epub 2007 Mar 31.

PMID:
17467344
50.

Chloroquine resistant P. falciparum prevalence is low and unchanged between 1990 and 2005 in Guinea-Bissau: an effect of high chloroquine dosage?

Ursing J, Schmidt BA, Lebbad M, Kofoed PE, Dias F, Gil JP, Rombo L.

Infect Genet Evol. 2007 Sep;7(5):555-61. Epub 2007 Mar 31.

PMID:
17467343

Supplemental Content

Support Center